ESSEN
DÜSSELDORF
COLOGNE



CLINIC MEETS BIOLOGY

WEST GERMAN LYMPHOMA SYMPOSIUM

PROGRAM

May 21–23, 2026

Conference Center Essen | Germany

Hybrid Event

CONTACT

Scientific lead and responsible for the program

Universitätsmedizin Essen

Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen (AöR)
Hufelandstraße 55, 45147 Essen (GER)

Unter the patronage of

Unter der Schirmherrschaft der
DGHO
DEUTSCHE GESELLSCHAFT FÜR HÄMATOLOGIE UND MEDIZINISCHE ONKOLOGIE

GLA German Lymphoma Alliance

Josep Carreras LEUKAEMIA Research Institute

In co-operation with

CANTAR

CRC | SFB 1530 Elucidation and targeting of pathogenic mechanisms in B cell malignancies

Meeting Office / Organizer and Contact

CSi Hamburg GmbH
Goernestraße 30, 20249 Hamburg (GER)
+49 40 30770 300
meetings@csihamburg.de

CSI HAMBURG CONFERENCES SYMPOSIA INCENTIVES

Venue

Conference Center Essen
Huyssenallee 53
45128 Essen (GER)
Nordrhein-Westfalen (NRW)

Hybrid Event

To follow the live stream with Q&A
www.lymphoma-symposium.de/stream
password: Lym-Sym26
(instructions will be shown)

Media library

Contributions - video on demand
available from
Thuesday, May 26, 2026
12:00 (CET)

WLAN

SSID: ClinicmeetsBiology
PW: Lymphoma2026

SCAN ME

WELCOME

Dear Colleagues and Friends

Welcome to the West German Lymphoma Symposium here in Essen.

Following the inaugural meeting in 2024, we are pleased to continue this format and to welcome you as part of a growing scientific community. The strong exchange during the first symposium confirmed the need for a dedicated forum that brings together regional and international expertise in preclinical and clinical lymphoma research.

The field is evolving rapidly. Advances in molecular understanding, improved mouse models and progress in preclinical drug development are reshaping research and treatment. New therapeutic strategies, including CAR-T cells, bispecific antibodies and next-generation small molecules, are increasingly entering clinical practice.

At the same time, the Comprehensive Cancer Centers CIO-ABCD (Aachen, Bonn, Cologne, Düsseldorf) and WTZ-EM (Essen, Münster) have further strengthened their collaboration. The establishment of the National Center for Tumor Disease West (NCT-West) in Essen and Cologne supports strong clinical and translational lymphoma programs and aims to inspire the next generation of researchers.

We are very pleased to have you here with us and hope you enjoy the scientific program and the discussions.

Abstracts submitted to this meeting are presented in short talks and the poster session, with selected contributions receiving awards.

With all our best wishes and warm regards
Conference chairs and program committee members

Christian Reinhardt
Bastian von Tresckow, Ralf Küppers, Stefan Alig
University Hospital Essen, West German Cancer Center

Peter Borchmann
University Hospital Cologne, Clinic for Internal Medicine
Oncology/Hematology

Sascha Dietrich
University Hospital Düsseldorf, Clinic for Hematology,
Oncology and Clinical Immunology

Ari M. Melnick
Josep Carreras Leukaemia,
Research Institute Barcelona

Day 1 | Thursday, May 21, 2026

from 12:30	Registration and Networking
1:45	**Opening and welcome** Scientific committee
2:00–4:05	**SESSION 1** **Epigenetic rewiring in aggressive lymphoma**
Chair	Christian Reinhardt, University Hospital Essen (GER)
2:00	**DNA-methylation based classification of lymphomas: A tool to come?** Reiner Siebert, Ulm University Hospital (GER)
2:25	**TBA** Björn Chapuy, Charité University Medicine Berlin (GER)
2:50	**Epigenetic regulation of lymphoma cell states** Michael R. Green, MD Anderson Cancer Center, Houston (USA)
3:15	**How the immune system becomes malignant reveals novel therapeutic vulnerabilities** Ari M. Melnick, Josep Carreras Leukaemia (ES)
3:40	**Decoding malignant B cell plasticity in aggressive lymphomas** Sandrine Roulland, CIML-Centre d' Immunologie, Marseille-Luminy (FR)
4:05–4:30	Break

4:30–7:00 **SESSION 2**
Harnessing the immune system for lymphoma therapy - I

Chairs
Georg Lenz, University Hospital Münster (GER)
Bastian von Tresckow, University Hospital Essen (GER)

4:30 **Targeting Oncogenic Chromatin Remodeling in Lymphoma**
Darko Barisic, Weill Cornell Medicine New York (USA)

4:55 **Reprogramming the lymphoma immune microenvironment for therapy**
Wendy Béguelin, Langone Health NYU, New York (USA)

5:20 **Cytokine-associated Immune Remodeling in Follicular Lymphoma Transformation**
Erin M. Parry, Harvard Medical School, Dana-Farber Cancer Institute, Boston (USA)

5:45 **Therapeutic targeting the lymphoma micro environment to improve CAR T-cell response in aggressive B-cell lymphoma**
Roland Ullrich, University Hospital Cologne (GER)

6:10 **The biology of high-risk B-cell malignancies**
Thomas Oellerich, University Medical Center Frankfurt (GER)

6:35 **Mechanisms of immune evasion in molecular subtypes of diffuse large B-cell lymphoma BA**
Margaret Shipp, Dana Farber/Harvard Cancer Center, Boston (USA)

7:00–9:00 **Get-together**

Day 2 | Friday, May 22, 2026

9:00–11:05 **SESSION 3**
Harnessing the immune system for lymphoma therapy - II
Chairs Peter Borchmann, University Hospital Cologne (GER)
Ralf Küppers, University Hospital Essen (GER)

9:00 **Recent developments in T-cell engaging antibodies for the treatment of B-cell lymphomas**
Martin Hutchings, University of Copenhagen (DK)

9:25 **B cell lymphoma development in the thymic niche**
Christian Steidl, Centre for Lymphoid Cancer, Vancouver (CAN)

9:50 **Primary analysis of the GHSG Pembro-CORE trial**
Bastian von Tresckow, University Hospital Essen (GER)

10:15 **Harnessing functional genomic screens to elucidate DLBCL biology**
Sebastian Scheich, University Hospital Frankfurt (GER)

10:40 **Novel mouse models of DLBCL**
Christian Reinhardt, University Hospital Essen (GER)

11:05–11:30 Break

11:30–1:35 **SESSION 4**
Towards chemo-free treatment of lymphoma
Chairs Stefan Alig, University Hospital Essen (GER)
Sascha Dietrich, University Hospital Düsseldorf (GER)

11:30 **Progress Made, Obstacles Remaining: anti-PD1 First-Line Treatment of cHL**
Paul Bröckelmann, University Hospital of Cologne (GER)

11:55 **Towards improved outcomes for p53 mutant blood cancers**
Gemma Kelly, Walter and Eliza Hall Institute of Medical Research (WEHI), Melbourne (AUS)

12:20 **Protogenomics and Precision Medicine**
James Phelan, National Cancer Institute, Bethesda (USA)

12:45 **Targeted Therapy Approaches in Aggressive B-cell Lymphoma**
Mark Roschewski, National Cancer Institute, Bethesda (USA)

1:10 **Frontline DLBCL Therapy in 2036: Chaos of Choice?**
Jason Westin, University of Texas MD Anderson Cancer, Center Houston (USA)

1:35–2:45 Break

2:45–4:25 **SESSION 5**
At the interface between biological and chemical engineering

Chairs
Ralf Küppers, University Hospital Essen (GER)
Christian Reinhardt, University Hospital Essen (GER)

2:45 **New targets and technologies for CAR-T cells in lymphoma**
Michael Hudecek, University Hospital Würzburg (GER)

3:10 **Same but different: on the role of B cells in cellular therapies**
Sebastian Kobold, LMU Klinikum, Munich (GER)

3:35 **Development of PROTACs as New Pharmaco logical Modalities for the Treatment of Cancer**
Stefan Knapp, Goethe-University Frankfurt (GER)

4:00 **Linking Elongation Factors and Lysine Acetyltransferases to Cancer Cell Death using Chemically Induced Proximity**
Roman Sarott, Max-Planck-Institute for Medical Research, Heidelberg (GER)

4:30–6:30 **POSTER PRESENTATION**

NEU beim
2L+ DLBCL NOS
ASCT-ungeeignet*

Roche

MIT DIESER OS-KURVE IST ALLES GESAGT**



COLUMVI® i.v. + GemOx **verdoppelt** das **mediane OS** auf **25,5 Monate**.[1,#]

Für mehr Informationen einfach QR-Code scannen.

COLUMVI® glofitamab

EMPOWERING **HEMATOLOGY**

POLIVY® ▼ COLUMVI® ▼ Lunsumio® ▼ GAZYVARO® PiaSky® ▼

Arzneimittel, die mit einem ▼ gekennzeichnet sind, unterliegen einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Bitte melden Sie Nebenwirkungen an die Roche Pharma AG unter grenzach.drug_safety@roche.com oder Fax +49 7624 14 3183 oder die zuständige Bundesoberbehörde unter www.pei.de oder www.bfarm.de (PEI/BfArM) oder Fax: +49 6103/77-1234 (PEI) bzw. Fax: +49 228/207-5207 (BfArM).

* Columvi in Kombination mit Gemcitabin und Oxaliplatin wird angewendet zur Behandlung erwachsener Patienten mit rezidiviertem oder refraktärem diffusem großzelligem B-Zell-Lymphom, das nicht anderweitig spezifiziert ist (DLBCL NOS), und Patienten, die nicht für eine autologe Stammzelltransplantation (ASCT) geeignet sind.

** In der STARGLO-Studie betrug das mediane, vom Prüfarzt beurteilte Gesamtüberleben (OS) 25,5 Monate (95%-KI: 18,3–NE) mit Columvi + GemOx, verglichen mit 12,9 Monaten (95%-KI: 7,9–18,5) mit R-GemOx (HR 0,62 [95%-KI: 0,43–0,88]); Datenschnitt Februar 2024.

Im Vergleich zu R-GemOx.

2L: zweite Therapielinie; **ASCT:** Autologe Stammzelltransplantation; **DLBCL:** diffuses großzelliges B-Zell-Lymphom; **GemOx:** Gemcitabin und Oxaliplatin; **i.v.:** intravenös; **NE:** nicht auswertbar; **NOS:** nicht anderweitig spezifiziert; **OS:** Gesamtüberleben; **R-GemOx:** Rituximab, Gemcitabin und Oxaliplatin.

1. Abramson JS, et al. Lancet. 2024; 404: 1940–54.

Zu den Pflichtangaben
go.roche.de/haema_PA

M-DE-00025798

Notes

4:30–6:30 **POSTER PRESENTATION**

The poster presentation is divided into 4 poster walks. Per poster: introduction/presentation 5 minutes + 5 minutes discussion. The 2 best poster presentations will be honored with a poster prize, during the closing ceremony

PO_A1 to PO_A11
Chair: Sascha Dietrich, University Hospital Duesseldorf (GER)

PO_A1 **DDX3X and DDX3Y dosage imbalance drives sex bias in Burkitt lymphoma.**
K. Helian[1], C. Gong[1], J. Coleman[2], V. Aggarwal[1], J. Krupka[1], S. Brocklesby[1], R. Gilbertson[2], D. Hodson[1]
[1] University of Cambridge, Cambridge Stem Cell Institute & Department of Haematology, Cambridge, United Kingdom
[2] University of Cambridge, CRUK Cambridge Institute & Department of Oncology, Cambridge, United Kingdom

PO_A2 **Cell clones containing BCOR frameshift mutations in the first coding exons of the gene retain BCOR protein expression**
Y. Yozbatiran[1], W. Sura[1], S. Sunder[1], Z. Drozdowska[1], K. Bednarek[1], M. Kostrzewska-Poczekaj[1], M. Giefing[1]
[1] Institute of Human Genetics, Polish Academy of Sciences, Cancer Genetics, Poznań, Poland

PO_A3 **NFDI4Immuno: A shared database for immunology research data**
A. Kadam[1], B. Budeus[1]
[1] Uniklinikum Essen, Institute of Cell Biology, Essen, Germany

PO_A4 **Functional role of AKT isoforms in Hodgkin Lymphoma**
M. Marra[1], R. Küppers[2], M. Jücker[1]
[1] University Medical Center Hamburg Eppendorf, Institute of Biochemistry and Signal Transduction, Hamburg, Germany
[2] University Duisburg-Essen, Institute of Cell Biology, Essen, North Rhine-Westphalia, Germany

PO_A5 **Establishing a scalable manufacturing process for genetically modified γδ T cells for preclinical research**
S. Nickel[1], K. Hoerster[1], M. Soldierer[2], H. Hanenberg[2, 3], C. Reinhardt[1], B. von Tresckow[1]
[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
[2] University Hospital Essen, Department of Pediatrics III, University Children's Hospital Essen, University Duisburg-Essen, Essen, Germany
[3] University Hospital Düsseldorf, Department of Otorhinolaryngology, Head & Neck Surgery, University Hospital Düsseldorf, Heinrich Heine University, Düsseldorf, Germany

PO_A6

Shift towards a more naive phenotype of the T-cell compartment in patients with aggressive B-cell non-Hodgkin lymphoma undergoing high-dose methotrexate therapy

V. C. Ridder[1], K. Hoerster[1], S. Nickel[1], P. B. Ridder[2], M. Teichert[1], J. Puthenparambil[1], H. C. Reinhardt[1], B. von Tresckow[1]

[1] Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, North Rhine-Westphalia, Germany

[2] Knappschaft Kliniken University Hospital Bochum, Center for Artificial Intelligence, Medical Informatics and Data Science, Bochum, North Rhine-Westphalia, Germany

PO_A7

Biomarker analysis to unravel mechanisms of resistance to glofitamab monotherapy in large B cell lymphoma

M. Nowicka[5], W. Leung[1], C. Carlo-Stella[2], M. Dickinson[3], M. Hutchings[4], E. Mulvihill[5], L. Lundberg[5], H. Hamidi[1], **A. Bottos**[5]

[1] Genentech, San Francisco, United States of America

[2] Humanitas University and IRCCS Humanitas Research Hospita, Milan, Italy

[3] Peter MacCallum Cancer Centre, Royal Melbourne Hospital and The University of Melbourne, Melbourne, Australia

[4] Rigshospitalet, Copenhagen, Denmark

[5] F. Hoffmann-La Roche, Basel, Switzerland

PO_A8

Mechanisms of humoral immune dysfunction in the Eμ-TCL1 adoptive transfer mouse model of chronic lymphocytic leukemia

A. Beyer[1], G. Knittel[1], S. Höfmann[1], A. W. Tabatabai[1], M. Möllmann[1], P.-H. Nguyen[3], R. Zölzer[3], S. P. Koziel[4], P.-M. Bruch[4], R. Küppers[2], H. C. Reinhardt[1]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

[2] University Hospital Essen, Institute for Cell Biology (Tumor Research), Essen, North Rhine-Westphalia, Germany

[3] Center for Molecular Medicine Cologne, Department I of Internal Medicine, Cologne, North Rhine-Westphalia, Germany

[4] University Hospital Düsseldorf, Department of Haematology, Oncology and Clinical Immunology, Düsseldorf, North Rhine-Westphalia, Germany

PO_A9

NR4A1 Loss Drives Immune Checkpoint Upregulation and CD8⁺ T Cell Dysfunction in Aggressive Lymphoma

K. Pansy[1], S. Haingartner[1], A. Deutsch[1]
[1] Medical University of Graz, Division of Hematology, Graz, Steiermark, Austria

PO_A10

Deciphering the Pathomechanisms of HIV-Associated Lymphomas

V. Berg[1], N. Kahlert[1], K. Danielzik[3], A. Rosenwald[4], G. Ott[5], A. Ross[12], M. Dampmann[2], S. Dolff[6], S. Hartmann[9], P. Möller[8], M. Hummel[10], S. Esser[7], L. Thurner[11], D. Hoffmann[3], B. Budeus[1], R. Küppers[1]
[1] University Hospital Essen, Institute of Cell Biology (Tumor Research), Essen, Germany
[2] University Hospital Essen, West German Tumour Centre, Essen, Germany
[3] University of Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, Germany
[4] University of Würzburg, Institute of Pathology, Würzburg, Germany
[5] Robert Bosch Hospital, Institute of Pathology, Stuttgart, Germany
[6] University Hospital Essen, Department of Infectiology, Essen, Germany
[7] University Hospital Essen, Department of Dermatology, Essen, Germany
[8] University Hospital Ulm, Department of Pathology, Essen, Germany
[9] University Hospital Essen, Department of Pathology, Essen, Germany
[10] Charité University Medicine, Institute of Pathology, Berlin, Germany
[11] University Hospital Saarland, José Carreras Center, Homburg, Germany
[12] University of Duisburg-Essen, Therapy Research in Neurogeriatrics, Essen, Germany

PO_A11

Immunosurveillance of premalignant germinal center B cells

L. Zhang[1, 2], M. S. Hung[1], O. Atkins[1], P. Artemov[3], A. Sochon[1], V. Boulat[1], H. C. Reinhardt[4], J. Okosun[3], D. P. Calado[1, 2]
[1] The Francis Crick Institute, London, United Kingdom
[2] Babraham Institute, Cambridge, United Kingdom
[3] Barts Cancer Institute, Queen Mary University of London, London, United Kingdom
[4] University Hospital Essen, Essen, Germany

PO_B1 to PO_B11
Chair: Bastian von Tresckow, University Hospital Essen (GER)

PO_B1

High-throughput, functional profiling of every DLBCL hotspot mutation in human germinal centre B cells

J. Mateos-Jaimez[1], G. Shevchenko[1], V. Jiménez-Martínez[2, 3], I. Moutsopoulos[1], E. Whittle[1], C. Gong[1], A. Yang[1], R. E. Fenner[1], M. Di Re[1], Y. Wang[1], M. Barile[1], X. Ju[1], L. M. Staudt[7], R. F. Pérez[2, 6], J. I. Martin-Subero[2, 5], D. J. Hodson[1]
[1] University of Cambridge, Department of Haematology, Cambridge, United Kingdom
[2] Institut d'Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
[3] University of Barcelona, Barcelona, Spain
[4] Institució Catalana de Recerca i Estudis Avançats, Barcelona, Spain
[5] Complutense University of Madrid, Department of Biochemistry and Molecular Biology, Madrid, Spain
[6] National Cancer Institute, Bethesda, United States of America

PO_B2

IGH enhancer RNAs - new players in B-cell lymphoma

A. Kompaniiets[1], J. Przybył[1], K. Rassek[1], M. Kasprzyk[1], W. Sura[1], N. Rozwadowska[1], A. Dzikiewicz-Krawczyk[1]
[1] Institute of Human Genetics Polish Academy of Sciences, Molecular Pathology, Poznań, Poland

PO_B3

Mechanisms of humoral immune dysfunction in CLL

M. M. Elbert[1], M. Dampmann[2, 3], N. Kahlert[1], J. von Tresckow[2, 4], A. Kibler[5], H. C. Reinhardt[2, 6], G. Knittel[2], B. Budeus[1], R. Küppers[1, 6]
[1] University Medicine Essen, Institute of Cell Biology (Cancer Research), Essen, North Rhine-Westphalia, Germany
[2] University Medicine Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany
[3] West German Cancer Center, Department of Medical Oncology, University Hospital Essen, Essen, North Rhine-Westphalia, Germany
[4] St. Josef-Hospital, Ruhr-University Bochum clinics, Bochum, North Rhine-Westphalia, Germany
[5] University Medicine Essen, Department of Immunodynamics, Institute for Experimental Immunology and Imaging, Essen, North Rhine-Westphalia, Germany
[6] German Cancer Research Center, German Cancer Consortium (DKTK), Essen, Baden-Württemberg, Germany

PO_B4

Mechanisms of immune evasion in aggressive B cell lymphomas

C. Brombach[1, 2], E. Sidiropoulou[1, 3], S. Kim[4, 5], N. Serin[6], N. Aubert[2], J. Ihlow[4], B. Chapuy[6], M. Seiffert[2], S. Sander[5, 1]

[1] German Cancer Research Center (DKFZ), Adaptive Immunity and Lymphoma, Heidelberg, Germany

[2] German Cancer Research Center (DKFZ), Molecular Genetics, Heidelberg, Germany

[3] German Cancer Research Center (DKFZ), Immune Diversity, Heidelberg, Germany

[4] Charité Universitätsmedizin Berlin, Institute of Pathology, Berlin, Germany

[5] University Medicine Greifswald, Greifswald, Comprehensive Cancer Center Mecklenburg Vorpommern, Greifswald, Germany

[6] Charité Universitätsmedizin Berlin, 6 Department of Hematology, Oncology, and Cancer Immunology, Campus Benjamin Franklin, Berlin, Germany

PO_B5

Hyperthermia increases ferroptosis susceptibility of diffuse large B-cell lymphoma

M. Franke[1], A. Schmitt[1], G. Lenz[1], S. Hailfinger[1]

[1] University Hospital Münster, Department of Medicine A, Hematology, Oncology and Pneumology, Münster, North Rhine-Westphalia, Germany

PO_B6

T-Cell Exhaustion and Myeloid Rewiring During Murine CLL Progression Uncovered by High-Dimensional Spectral Cytometry

H. Briesch[1, 3], M. Coelho[1, 3], N. Aubert[1], A. Floerchinger[1, 3], D. Medina Gil[1], M. Günter[4], M. Zapatka[2], S. E. Autenrieth[4], M. Seiffert[1]

[1] German Cancer Research Center (DKFZ), Immune Modulation in Cancer, Heidelberg, Germany

[2] German Cancer Research Center (DKFZ), Molecular Genetics, Heidelberg, Germany

[3] Heidelberg University, Faculty of Biosciences, Heidelberg, Germany

[4] German Cancer Research Center (DKFZ), Dendritic cells in Infection and Cancer, Heidelberg, Germany

PO_B7

An extended ex vivo HSC expansion platform enables rapid, multiplex in vivo functional genomics for lymphoma

H. Bilboe[1], C. Gong[1], A. Wilkinson[1], D. Hodson[1]

[1] University of Cambridge, Department of Haematology, Cambridge, United Kingdom

PO_B8

Identification and characterization of somatic mutations in *ZC3H12A* in ABC DLBCL

F. Eberstadt[1], M. Wang[2], B. Chapuy[2], D. Krappmann[1]

[1] Helmholtz Munich, SAT - AG Krappmann, Munich, Bavaria, Germany

[2] Charité Universitätsmedizin Berlin, Translationale Lymphomforschung, Leitung Lymphome, Berlin, Germany

PO_B9

In search of lost ORFs: high confidence map of noncanonical Open Reading Frames in lymphoid cells

J. A. Krupka[1, 2], E. Whittle[1, 2], K.H. J. Tan[1, 2], G. Shevchenko[1, 2], R. Jackson[1, 2], C. Gong[1, 2], J. Gao[1, 2], D. J. Hodson[1, 2]
[1] University of Cambridge, Department of Haematology, Cambridge, United Kingdom
[2] University of Cambridge, Cambridge Stem Cell Institute, Cambridge, United Kingdom

PO_B10

Circulating Tumor DNA Reveals Lymphoma-Associated Mutations Long Before Clinical Diagnosis

N. Veltmaat[1, 3], Y. Zhong[1, 3], I. van Zeventer[1], J. Kluiver[2, 3], A. Diepstra[2, 3], A. van den Berg[2, 3], W. Plattel[1, 3], M. Nijland[1, 3]
[1] University Medical Center Groningen, Hematology, Groningen, Netherlands
[2] University Medical Center Groningen, Pathology and Medical Biology, Groningen, Netherlands
[3] University Medical Center Groningen, Lymphoma Research Groningen, Groningen, Netherlands

PO_B11

In vivo production of bispecific antibodies against hematological malignancies

Y. Yang[1], M. Freihammer[1], R. Flümann[1], A. Lütz[1], J. Petri[1], M. Michalik[1], S. Borchmann[1, 2]
[1] University of Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Cologne, Germany
[2] German Hodgkin Study Group, Cologne, Germany

PO_C1 to PO_C11
Chair: Stefan Alig, University Hospital Essen (GER)

PO_C1

Defining Functional Subgroups and Novel Oncogenic Addictions in Burkitt Lymphoma via Genome-wide CRISPR/Cas9 Screening

A. K.P. Götze[1], S. P. Chillappagari[1], S. Becker[1], R. Kumar[2], M. Braun[3], A. Bräuninger[1], D. Körholz[3], S. Gattenlöhner[1], R. Schmitz[1]
[1] Justus-Liebig University, Institute for Pathology, Gießen, Germany
[2] Indian Institute of Technology, Department of Biotechnology, Hyderabad, India
[3] Justus-Liebig University, Pediatric Hematology and Oncology Department, Gießen, Germany

PO_C2

Elucidation of transcriptomic tumor cell heterogeneity and microenvironment in classic Hodgkin lymphoma

F. Schramm[1], S. Klotz[1], B. Budeus[1], L. Beeck[1], M. Weniger[1], P. Bröckelmann[2], R. Küppers[1]
[1] University medicine Essen, Institute for Cellbiology (Tumor Research), Essen, Germany
[2] University Hospital of Cologne, Max Planck Institute for Biology of Ageing, Cologne, Germany

PO_C3

Prognostic Value of the Glasgow Prognostic Score in a Slovene Cohort of Patients with Nodal T-Follicular Helper Cell Lymphoma

G. Gašljević[1, 2], R. Arko[3], E. Erzar[4], V. Sindi-Ivanova[5], S. Dirnhofer[5], A. Tzankov[5], V. Kloboves-Prevodnik[6, 2], P. Dora[1], M. Kokelj[6], L. Boltežar[3]
[1] Institute of Oncology Ljubljana, Department of Pathology, Ljubljana, Slovenia
[2] University of Maribor, Faculty of Medicine, Maribor, Slovenia
[3] Institute of Oncology Ljubljana, Department of Medical Oncology, Ljubljana, Slovenia
[4] Tissue Typing Centre, Slovenian Institute for Transfusion Medicine, Ljubljana, Slovenia
[5] University Hospital Basel, University of Basel, Institute of Medical Genetics and Pathology, Basel, Switzerland
[6] Institute of Oncology Ljubljana, Department of Cytopathology, Ljubljana, Slovenia

PO_C4

Rituximab-induced liquid biopsy signatures inform on cellular and microenvironmental contexts in B-Cell Lymphoma patients

S. Tehrani Fateh[1, 2], G. Greiner[1, 2], W.-K. Hofmann[2], **K. Clemm von Hohenberg**[1, 2]
[1] German Cancer Research Center (DKFZ) Heidelberg, Junior Clinical Cooperation Unit Translational Lymphoma Research, Mannheim, Germany
[2] University Medicine Mannheim, Departmant of Hematology/Oncology, Mannheim, Germany

PO_C5 **Niche eviction via CD49d targeting sensitises BM-tropic DLBCL to CD3×CD20 bispecifics**

N. Aubert[1], H. Briesch[1], A. Floerchinger[1], D. Calado[2, 3], M. Seiffert[1]
[1] DKFZ, B060 Molecular Genetics, Heidelberg, Baden-Württemberg, Germany
[2] Francis Crick Institute, Immunity & Cancer Laboratory, London, United Kingdom
[3] Babraham Institute, Cambridge, United Kingdom

PO_C6 **B Cell Differentiation in the Germinal Centre Reaction**

A.-K. Schnormeier[1], B. Höing[3], B. Budeus[1], M. Weniger[1], D. Hoffmann[2], R. Küppers[1]
[1] University of Duisburg-Essen, Institute of Cell Biology (Tumour Research), Essen, Germany
[2] University of Duisburg-Essen, Bioinformatics and Computational Biophysics, Essen, Germany
[3] University Medical Centre, Otolaryngology, Essen, Germany

PO_C7 **The Clinico-Genomic Lymphoma Dataset Explorer (CLYDE): A Comparative Analysis of High-Throughput DNA Sequencing Datasets of Diffuse Large B-Cell Lymphoma**

J. Zhou[1, 2], F. Ullrich[1], M. Nezamabadi[1, 2], C. Reinhardt[1], B. von Tresckow[1], E. Kocakavuk[1, 2]
[1] University Hospital Essen, Dept of Hematology and Stem Cell Transplantation,West German Cancer Center, NCT-West, Essen, Germany
[2] University Hospital Essen, Institute for AI in Medicine (IKIM), Essen, Germany

PO_C8 **Zonation mapping of the neuro-immune-tumor crosstalk in primary central nervous system lymphoma via spatial transcriptomics**

Q. Shi[1, 2], Y. Su[1, 2], Y. Zhou[3], C. Reinhardt[1], B. von Tresckow[1], F. Rambow[2], C. Mlynarczyk[3], E. Kocakavuk[1, 2]
[1] Universitätsklinikum Essen, Hematology and Stem Cell Transplantation, West German Cancer Center, Essen, Germany
[2] Universitätsklinikum Essen, Institute for Artificial Intelligence in Medicine, Essen, Germany
[3] Yale University, Yale School of Medicine, CE, United States of America

PO_C9

Single-nucleus RNA-sequencing of central nervous system lymphoma (CNSL)

Y. Su[1, 2], H. Dong[2], F. Ullrich[1], K. Keyvani[3], S. Hartmann[4], C. Reinhardt[1], B. von Tresckow[1], F. Rambow[2], C. Mlynarczyk[5], E. Kocakavuk[1, 2]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

[2] University Hospital Essen, Institute for AI in Medicine, Essen, North Rhine-Westphalia, Germany

[3] University Hospital Essen, Department of Neuropathology, Essen, North Rhine-Westphalia, Germany

[4] University Hospital Essen, Department of Pathology, Essen, North Rhine-Westphalia, Germany

[5] Yale University, Yale School of Medicine, New Haven, Connecticut, United States of America

PO_C10

Exploring NR4A1-associated transcriptional programs in lymphoma at single-cell resolution

A. Zupo[1], S. Haingartner[1], J. Feichtinger[2], F. Vagena[3], K. Pansy[1], A. Deutsch[1]

[1] Medical University of Graz, Department of Hematology, Graz, S teiermark, Austria

[2] Medical University of Graz, Division of Cell Biology, Histology and Embryology, Gottfried Schatz Research Center, Graz, Steiermark, Austria

[3] Medical University of Graz, Institute of Pathology, Graz, Steiermark, Austria

PO_C11

Loss of *ETV6* enhances lymphomagenesis in a murine model of diffuse large B cell lymphoma in a cell-of-origin dependent manner

S. Höfmann[1], A. Tabatabai[1], R. Flümann[2, 3], S. Klein[1], I. Kisis[1], R. Öllinger[4], M. Möllmann[1], M. Hartnack[1], S. Kesper[1], A. Arora[1], B. von Tresckow[1], R. D. Jachimowicz[2, 5], R. Rad[4, 6], G. Knittel[1], H. C. Reinhardt[1]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

[2] University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology, Aachen Bonn Cologne Duesseldorf, North Rhine-Westphalia, Germany

[3] University of Cologne, Center for Molecular Medicine, Cologne, North Rhine-Westphalia, Germany

[4] Technische Universität München, Institute of Molecular Oncology and Functional Genomics, School of Medicine, Munich, Bavaria, Germany

[5] Max Planck Institute for Biology of Ageing, Cologne, North Rhine-Westphalia, Germany

[6] Technische Universität München, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Munich, Bavaria, Germany

PO_D1 to PO_D11
Chair: Ralf Küppers, University Hospital Essen (GER)

PO_D1

Generation of Faithful Autochthonous Mouse Models of Mantle Cell Lymphoma

N. A. Mönig[1, 2], C. M. Gräf[1, 2], P. J. Bröckelmann[1, 2], C. Bruzeau[1], Y. Taskiran[1], M. Reese[1, 2], A. Becker[1, 2], G. Knittel[4], H. C. Reinhardt[4], M. Thelen[1, 2], R. D. Jachimowicz[1, 2]

[1] Max Planck Institute for Biology of Ageing, Mechanisms of DNA Repair, Cologne, North Rhine-Westphalia, Germany
[2] University of Cologne, Department I of Internal Medicine, Cologne, North Rhine-Westphalia, Germany
[3] University Duisburg-Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

PO_D2

Linear ubiquitin is critical for transformation and immune evasion of diffuse large B-Cell Lymphoma

D. Bonasera[1, 2], J. Saggau[1, 2], A. Langpape[1, 2], J. Valiulis[3], A. Florin[4], M. Peifer[3], J. Löber[5], B. Chapuy[5, 6], R. Büttner[4], H. C. Reinhardt[7], E. Rieser[2, 1], A. Montinaro[8], G. Liccardi[1, 2], H. Walczak[1, 2]

[1] Uniklinik, University of Cologne, Institute of Biochemistry I, Cologne, North Rhine-Westphalia, Germany
[2] Uniklinik, University of Cologne, CECAD Cluster of Excellence, Cologne, North Rhine-Westphalia, Germany
[3] University of Cologne, Department of Translational Genomics, Cologne, North Rhine-Westphalia, Germany
[4] Uniklinik, University of Cologne, Institute of Pathology, Cologne, North Rhine-Westphalia, Germany
[5] Charité-Universitätsmedizin Berlin, Department of Hematology, Oncology and Tumorimmunology, Berlin, Berlin, Germany
[6] Charité-Universitätsmedizin Berlin, German Cancer Consortium, Berlin, Berlin, Germany
[7] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany
[8] University College London, UCL Cancer Institute, London, United Kingdom

PO_D3

Genetic lesions in nodular lymphocyte-predominant Hodgkin lymphoma and T cell/histiocyte-rich large B-Cell Lymphoma identified by whole genome sequencing

T. Rausch[3], H. Schäfer[1], J. Bein[5], F. Mölder[6], L. Beeck[6], B. Kölsch[1], S. Borchert[1], V. Benes[3], T. Halbsguth[2], U. Brunnberg[2], T. Oellerich[2], T. Tousseyn[4], M. Ponzoni[7], M.-L. Hansmann[5], J. Köster[6], R. Küppers[6], **S. Hartmann**[1]

[1] University Hospital Essen, Institute for Pathology, Essen, North Rhine-Westphalia, Germany
[2] University Hospital Frankfurt, Internal Medicine 2, Frankfurt, Hesse, Germany
[3] EMBL, Heidelberg, Baden-Württemberg, Germany
[4] University Hospital KU Leuven, Pathology, Leuven, Belgium
[5] University Hospital Frankfurt, Frankfurt, Hesse, Germany
[6] University Hospital Essen, Essen, North Rhine-Westphalia, Germany
[7] Scientific Institute San Raffaele, Pathology, Milan, Italy

PO_D4

Targeting MCT1 to Overcome Immunometabolic Resistance in Diffuse Large B-Cell Lymphoma

A. Lütz[1], J. Petri[1], L. Schiffer[1], S. Lund[2], T. Behringer[2], S. Seghezzi[3], C. Orschel[1], A.-C. Neumann[1, 3], S. Borchmann[1], R. Ullrich[1], S. Scheich[2], C. Frezza[3], R. Flümann[1]

[1] University of Cologne, Department I of Internal Medicin, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
[2] University Hospital Frankfurt, Oncology Hematology, Frankfurt, Germany
[3] University of Cologne, Cluster of Excellence for Aging Research CECAD, Cologne, Germany

PO_D5

IRF2BP2: A novel tumor suppressor in diffuse large B-Cell Lymphoma

A. Tabatabai[1], M. Möllmann[1], M. Hartnack[1], G. Knittel[1], C. Reinhardt[1]

[1] University Hospital Essen, Essen, Germany

PO_D6

Optimising Base Editing to Identify Novel Translated Microproteins in B Cell Lymphoma

E. G. Whittle[1], J. Krupka[1], G. Scevchenko[1], R. Jackson[1], D. J. Hodson[1]

[1] Univeristy of Cambridge, Department of Haematology, Cambridge, United Kingdom

PO_D7

Comprehensive analysis of bridging to CAR T-cell therapy in large B-Cell Lymphoma with conventional treatment or CD3xCD20 bispecific antibodies

M.A.-C. Neumann[1, 2], H. K. Zieger[4], R. Fluemann[1, 3], N. Sieg[1, 5], A. Luetz[1, 5], J.K. Schleifenbaum[1, 2], S. Theobald[5], M. Thelen[6, 7], C.-A. Voltin[8], J. Ferdinandus[1, 2], M. Teichert[4], K. Hörster[4], V.C. Ridder[4], E. Shumilov[9], J. K. Scholz[10], H. Huber[11, 12], R. I. Wurm-Kuczera[13], F. Eigendorff[14], F. Eisele[15], G. Magno[16, 17], P. Schommers[1], M. Szameitat[1], J. Schneider[1], S. Seghezzi[18], D. Stahl[1, 2], P.J. Bröckelmann[19, 20], D. Bachurski[1, 2], N. Kutsch[1, 2], P. Gödel[1, 2], J. Meinel[21], J. Rosenbrock[22], I. Halmer[1], M. Gräf[1, 2], M. Reese[1, 20], H. C. Reinhardt[4], G. Lenz[9], F. Müller[10], B. Chapuy[13], U. Schnetzke[14], M. Topp[15], V. Bücklein[16], D.A. Eichenauer[1], S. Borchmann[1, 19], J.-M. Heger[1, 2], P. Borchmann[1, 2], R.D. Jachimowicz[1, 20], **B. von Tresckow**[4]

[1] Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Düsseldorf, University of Cologne, Medical Faculty and University Hospital Cologne, Cologne, Germany
[2] Cologne Lymphoma Working Group (CLWG), Cologne, Germany
[3] University of Cologne, Faculty of Medicine and University Hospital Cologne, Institute for Metabolomics in Ageing, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany
[4] Department of Hematology and Stem Cell Transplantation, West German Cancer Center and German Cancer consortium (DKTK partner site Essen), University Hospital Essen, University of Duisburg-Essen, Essen, Germany
[5] Institute for Molecular Immunology, University of Cologne, Cologne, Germany
[6] Department of General, Visceral, Thoracic, and Transplantation Surgery, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
[7] Center for Molecular Medicine Cologne, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
[8] Department of Nuclear Medicine, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
[9] Department of Medicine A, Hematology, Oncology and Pneumology, University Hospital Münster, Germany
[10] Department of Medicine 5 - Haematology and Oncology University Hospital Erlangen, Erlangen, Germany
[11] Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
[12] Department of Internal Medicine III, Division of CLL, Ulm University, Ulm, Germany
[13] Department of Hematology, Oncology and Cancer Immunology Charité Charité - Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany
[14] Klinik für Innere Medizin II, Abteilung Hämatologie und Internistische Onkologie, Universitätsklinikum Jena, Jena, Germany
[15] Universitätsklinikum Würzburg, Medizinische Klinik und Poliklinik II, Würzburg, Germany
[16] LMU University Hospital, Department of Medicine III, Hematology/ Oncology, Munich, Munich, Germany
[17] German Cancer Consortium (DKTK), Partner Site Munich, Munich, Germany
[18] University of Cologne, Faculty of Mathematics and Natural Sciences, Institute for Genetics, Cluster of Excellence Cellular Stress Responses in Aging-associated Diseases (CECAD), Cologne, Germany
[19] German Hodgkin Study Group (GHSG), Cologne, Germany
[20] Max Planck Institute for Biology of Ageing, Cologne, Germany
[21] Institute of Pathology, University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany
[22] Department of Radiation Oncology and Cyberknife Center, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany

PO_D8

Building a Genomic Meta-Cohort of 1,029 Primary CNS Lymphoma: Age-Associated Mutational Patterns from 27 Harmonized Cohorts

M. Tembrink[1, 2], N. Freund[1], C. Mlynarczyk[4], S. Alig[1], C. Reinhardt[1], B. von Tresckow[1], B. Pelzer[3], E. Kocakavuk[1, 2]

[1] University Hospital Essen, Department of Hematology and Stem Cell Transplantation, Essen, North Rhine-Westphalia, Germany

[2] University Hospital Essen, Institute for AI in Medicine (IKIM), Essen, North Rhine-Westphalia, Germany

[3] Cornell University, Weill Cornell Medicine, Ithaca, New York, United States of America

[4] Yale University, Yale School of Medicine, New Haven, Connecticut, United States of America

PO_D9

Genomic landscape of pediatric and adolescent Hodgkin lymphoma

M. Dörrbecker[1], T. Jox[2], A. Rredhi[2], P. Görtz[2], R. Schmitz[2], D. Körholz[3], C. Mauz-Körholz[3], S. Gattenlöhner[2], M. Bartkuhn[1], **A. Bräuninger**[2]

[1] Justus Liebig University Giessen, Biomedical Informatics and Systems Medicine Science Unit for Basic and Clinical Medicine, Giessen, Germany

[2] Justus Liebig University Giessen, Institute for Pathology, Giessen, Germany

[3] Justus Liebig University Giessen, Pediatric Hematology and Oncology Department, Giessen, Germany

PO_D10

Targeting Wnt/β-Catenin–PI3K/AKT Crosstalk: Insight into lineage restricted B-Cell Oncogenic Co-Operation

S. Kumar[1], P. Munch[1], E. Zurkowski[1], B. Clausen[1], T. Wunderlich[2], N. Hovelmeyer[1]

[1] Universitätsmedizin der Johannes Gutenberg-Universität, Institute for Molecular Medicine, Mainz, Rhineland-Palatinate, Germany

[2] Max Plank Institute for Metabolism Research, Obesity and Cancer, Cologne, North Rhine-Westphalia, Germany

PO_D11

BRD4 inhibition sensitizes diffuse large B-Cell Lymphoma cells to ferroptosis

A. Schmitt[1], H. Junge[1], N. Kreienkamp[1], P. Klener[2], A. Dolnikova[2], G. Lenz[1], S. Hailfinger[1]

[1] University Hospital Münster, Department of Medicine A, Münster, North Rhine-Westphalia, Germany

[2] Charles University Prague, Institute of Pathological Physiology, Prague, Czech Republic

Gemeinsam
Grenzen bei Krebs
verschieben

FORTSCHRITTE
entstehen im Miteinander

Engagement, Innovationsgeist und Partnerschaften ermöglichen es uns, Menschen mit Krebs neue Lebensperspektiven zu eröffnen. Denn unsere konsequente Forschung führt zu Medikamenten, mit denen **stetig der Therapiestandard verbessert** werden kann.

Doch echte Fortschritte entstehen vor allem im **Miteinander** – mit Wissenschaft, Medizin und Patientenorganisationen.

FÜR EINE ZUKUNFT VON MENSCHEN MIT KREBS.

abbvie

DE-EPCOR-260003 04/2026

9:00-11:05 **SESSION 6**
Molecular characterization and dynamic disease monitoring in lymphoma

Chairs Ari M. Melnick, Josep Carreras Leukaemia (ES)
Sandrine Roulland, CIML-Centre d' Immunologie, Marseille-Luminy (FR)

9:00 **Minimally Invasive Technologies for Profiling Lymphomas and Their Microenvironment**
Ash A. Alizadeh, Stanford University / Stanford Comprehensive Cancer Center (USA)

9:25 **Molecularly Defined Classic Hodgkin Lymphoma Subtypes**
Stefan Alig, University Hospital Essen (GER)

9:50 **Molecular characterization and liquid biomarker strategies in primary CNS lymphoma**
Florian Scherer, University of Freiburg (GER)

10:15–10:25 **Short talk I**
Bypassing Heterogeneity: Targeting a Lineage-Specific Dependency in Germinal Centre–Derived B-Cell Lymphoma
R. A. Jackson; E. G. Whittle; H. Runge; W. Zhou; Y. Wang, Cambridge (UK); S. Kolsuz, Istanbul (TR); D. Hodson, Cambridge (UK)

10:30–10:40 **Short talk II**
Relapse-founding progenitor cells in follicular lymphoma
O. Atkins; M.S. Hung; O.-R. Song; B. Chen; B. Maybury; C. Edmondson, London (UK); B. Tesson, Pierre-Bénite (FR); S. Huet, Lyon (FR); G. Salles, New York (USA); M. Howell, London (UK); H. C. Reinhardt, Essen (GER); J. Fitzgibbon; J. Okosun; L. Zhang, London (UK); D. P. Calado, London and Cambridge (UK)

10:40 **Developing multi-agent therapies targeting oncogenic pathways in aggressive lymphomas**
Louis Staudt, National Cancer Institute Bethesda (USA)

11:05–11:35 Break

11:35-2:30 **SESSION 7**
Molecular decoding of lymphomagenesis

Chairs Christian Reinhardt, University Hospital Essen (GER)
Margaret Shipp, Dana Farber/Harvard Cancer Center, Boston (USA)

11:35 **Mouse models of mantle cell lymphoma**
Ron Jachimowicz, University Hospital Cologne (GER)

12:00 **Mechanisms of germinal center B cell competition and CNS infiltration in DLBCL**
Coraline Mlynarczyk, Cancer Center Yale University School of Medicine / New Haven (USA)

12:25 **Molecular characterisation and heterogeneity of follicular lymphoma transformation**
Jessica Okosun, Queen Mary University of London (UK)

12:50 **Genetics-driven Epigenetic Deregulation in B cell lymphomas**
Laura Pasqualucci, Columbia University New York (USA)

1:15 **Deciphering the Genomics of Aggressive Lymphoma**
Daniel Hodson, University of Cambridge (UK)

1:40 **The Roads Less Traveled: Extra-Follicular Pathways in DLBCL Development**
Benedikt Pelzer, University Hospital Essen (GER)

2:05 **Mouse models of genetically-driven DLBCL immune states and immunotherapy outcomes**
José Ángel Martínez Climent, University of Navarra (ES)

2:30 **Closing remarks**
Farewell and Goodbye

Jaypirca®
pirtobrutinib
A Lilly Medicine

In der Onkopedia-Leitlinie in der 2L bei CLL post-cBTKi* empfohlen[4]

Bei r/r MCL & r/r CLL post-cBTKi zugelassen[1]

Wenn ein kovalenter BTK-Inhibitor* bei chronischer lymphatischer Leukämie (CLL) keine Option mehr ist+

Die Vorteile der BTK-Inhibition mit Jaypirca® nutzen[1]

Nachgewiesene Wirksamkeit[1,2]

14.0
Monate mPFS
(95 %-KI: 11.2, 16.6)
vs. 8.7 Monate
(95 %-KI: 8.1, 10.4)
für IdR/BR[2]

24.0
Monate mTTNT¶
(95 %-KI: 17.8, 29.7)
vs. 10.9 Monate
(95 %-KI: 8.7, 12.5)
für IdR/BR[2]

Günstiges Verträglichkeitsprofil[1,2]

5%
Abbruchrate
aufgrund von behandlungsbedingten UEs
vs. 21 % für IdR/BR[2a]

Einfaches Dosierschema[1]

1 ×
täglich
Zwei Tabletten

¶ Sekundärer Endpunkt. Erlaubt keine statistischen Schlussfolgerungen.[2]

Jaypirca® Pflichttext

Jaypirca® als Monotherapie ist indiziert zur Behandlung von erwachsenen Patient:innen mit rezidiviertem oder refraktärem Mantelzell-Lymphom (MCL) und erwachsenen Patient:innen mit rezidivierter oder refraktärer chronischer lymphatischer Leukämie (CLL), die zuvor mit einem Bruton-Tyrosinkinase (BTK)-Inhibitor behandelt wurden.[1]

* Ibrutinib, Acalabrutinib, Zanubrutinib.[3] + «Keine Option mehr ist» bezieht sich auf eine Krankheitsprogression.[1] [a] Zahlen sind gerundet.

2L: Zweitlinie; BTK: Bruton-Tyrosinkinase; **BTKi:** BTK-Inhibitor; **cBTKi:** kovalenter Bruton-Tyrosinkinase-Inhibitor; **IdR/BR:** Idelalisib plus Rituximab oder Bendamustin plus Rituximab; **KI:** Konfidenzintervall; **MCL:** Mantelzell-Lymphom; **mPFS:** medianes progressionsfreies Überleben; **mTTNT:** mediane Zeit bis zur nächsten Behandlung; **r/r:** rezidiviert oder refraktär; **UE:** Unerwünschte Ereignisse.

Referenzen: 1. Jaypirca® Fachinformation (aktueller Stand). **2.** Sharman JP, et al. J Clin Oncol. 2025;00(00):1–12. **3.** Wen T, et al. Leukemia. 2021;35(2):312-332.
4. Chronische Lymphatische Leukämie (CLL) - Onkopedia.
https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@@guideline/html/index.html. Letzter Zugriff: Januar 2026.

PP-PT-DE-0330 März 2026

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Dies ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden.

Lilly A MEDICINE COMPANY

Notes

STEFAN **ALIG**

Department of Hematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
Essen, GER

ASH A. **ALIZADEH**

Professor of Medicine
Stanford University | Stanford Comprehensive Cancer Center
Stanford, USA

DARKO **BARISIC**

Division of Hematology & Medical Oncology
Weill Cornell Medicine
New York, USA

WENDY **BÉGUELIN**

New York City University
Langone Health
New York, USA

[1]All information as provided by the respective speaker.

Faculty | Speakers, in alphabetical order[1]

PETER **BORCHMANN**

Clinic for Internal Medicine Oncology/ Haematology
University Hospital Cologne
Cologne, GER

PAUL **BRÖCKELMANN**

Department I of Internal Medicine and German Hodgkin Study Group
University Hospital of Cologne
Cologne, GER

BJÖRN **CHAPUY**

Charité University Medicine Berlin
Berlin, GER

SASCHA **DIETRICH**

Director of the Clinic for Haematology, Oncology and Clinical Immunology
University Hospital Düsseldorf
Düsseldorf, GER

Faculty | Speakers, in alphabetical order[1]

MICHAEL **GREEN**

Professor and Vice Chair for Research
Department of Lymphoma & Myeloma
University of Texas MD Anderson Cancer Center
Houston, USA

DANIEL **HODSON**

Cambridge Stem Cell Institute
University of Cambridge
Cambridge, UK

MICHAEL **HUDECEK**

Medical Clinic and Polyclinic II
Chair of CI /NCT WERA
University Hospital Würzburg
Würzbug, GER

MARTIN **HUTCHINGS**

Senior consultant, Department of Haematology and Phase 1 Unit
Rigshospitalet, Copenhagen
Professor, Department of Clinical Medicine
University of Copenhagen
Copenhagen, DK

[1]All information as provided by the respective speaker.

RON **JACHIMOWICZ**

Clinic for Internal Medicine Oncology/Hermatology
Max-Planck-Institute for Biology of Ageing
University Hospital Cologne
Cologne, GER

GEMMA **KELLY**

Professor
Walter and Eliza Hall Institute of Medical Research
Melbourne, AUS

STEFAN **KNAPP**

Professor of Pharmaceutical Chemistry
CSO Structural Genomics Consortium, Frankfurt
Institute of Pharmaceutical Chemistry
Goethe-University Frankfurt
Frankfurt, GER



SEBASTIAN **KOBOLD**

Division of Clinical Pharmacology
LMU Klinikum München
Munich, GER

RALF **KÜPPERS**

Deputy Managing Director
Institute for Cell Biology (cancer research)
University Hospital Essen
Essen, GER

GEORG **LENZ**

Director
University Hospital Münster
Münster, GER

JOSÉ ÁNGEL **MARTÍNEZ CLIMENT**

University of Navarra
Navarra, ES

ARI M. **MELNICK**

Director
Josep Carreras Leukaemia
Research Institute
Barcelona, ES

[1]All information as provided by the respective speaker.

CORALINE **MLYNARCZYK**

Assistant Professor of Medicine
Yale Cancer Center & Center of Molecular & Cellular Oncology
Yale University School of Medicine
New Haven, USA

THOMAS **OELLERICH**

Director
Department of Hematology, Oncology, Hemostaseology,
Rheumatology and Infectious Diseases
University Medical Center Frankfurt
Frankfurt, GER

JESSICA **OKOSUN**

Professor of Translational Cancer Research
Barts Cancer Institute
Queen Mary University of London
London, UK

ERIN M. **PARRY**

Assistant Professor of Medicine, Harvard Medical School
Phisician, Dana-Farber Cancer Institute
Boston, USA

Faculty | Speakers, in alphabetical order[1]

LAURA **PASQUALUCCI**

Professor of Pathology and Cell Biology
Institute for Cancer Genetics
Columbia University
New York, USA



BENEDIKT **PELZER**

West German Cancer Center
University Hospital Essen
Essen, GER

JAMES D. **PHELAN**

Center for Cancer Research
National Cancer Institute
Bethesda, USA

CHRISTIAN **REINHARDT**

Director, Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
Essen, GER

[1]All information as provided by the respective speaker.

MARK **ROSCHEWSKI**

Memorial Sloan Kettering Cancer Center
New York, USA

SANDRINE **ROULLAND**

Centre d´Immunologie Marseille-Luminy
Parc Scientifique et Technologique de Luminy
Marseille, FR

ROMAN C. **SARROT**

Max-Planck-Institute for Medical Research
Heidelberg, GER

SEBASTIAN **SCHEICH**

Department of Hematology and Oncology
University Hospital Frankfurt
Frankfurt, GER

FLORIAN **SCHERER**

Department of Hematology and Oncology
University Medical Center Freiburg
Freiburg, GER



MARGARET **SHIPP**

Douglas Miller Chair in Lymphoma
Dana-Farber Cancer Institute
Professor, Harvard Medical School
Boston, USA

REINER **SIEBERT**

Professor of Human Genetics
Director, Institute of Human Genetics
Vice-Director, Center of Rare Diseases
Ulm University Medical Center
Ulm, GER

LOUIS M. **STAUDT**

Director, Center for Cancer Genomics
Chief, Lymphoid Malignancies Branch
National Cancer Institute
Bethesda, USA

[1]All information as provided by the respective speaker.

Faculty | Speakers, in alphabetical order[1]

CHRISTIAN **STEIDL**

Professor, Department of Pathology and Laboratory Medicine
University of Britisch Columbia
Vancouver, CAN



ROLAND **ULLRICH**

Clinic for Internal Medicine
University Hospital Cologne
Cologne, GER

BASTIAN **VON TRESCKOW**

Deputy Director, Department of Haematology and Stem Cell Transplantation
West German Cancer Center
University Hospital Essen
Essen, GER

JASON **WESTIN**

Professor, Department of Lymphoma & Myeloma
Director, Lymphoma Clinical Research
Section Chief, Aggressive and Indolent Lymphoma
University of Texas MD Anderson Cancer Center
Houston, USA

MAIN SPONSORS

THANK YOU ALL VERY MUCH

In accordance with the recommendations of the German Medical Association, the Association of Scientific Medical Societies and the Voluntary Self-Regulation of the Pharmaceutical Industry (FSA Code of Conduct for Healthcare Professionals, Section 20 (5)), the contributions (net amounts, before deduction of costs) of the industry partnerships are disclosed. The above-mentioned companies are participating in the West German Lymphoma Symposium in return for services. Net amounts, before deduction of costs. Total cost of the conference: approx. € 250,000. AbbVie Deutschland GmbH & Co. KG - € 50,000, BeOne Medicines Germany GmbH - € 5,000, Bristol-Myers Squibb GmbH & Co. KGaA - € 10,000, GILEAD Science GmbH - € 5,000, Janssen-Cilag GmbH/ Johnson & Johnson - € 50,000, Lilly Deutschland GmbH - € 50,000, MSD - € 5,000, Roche Pharma AG - € 50,000, sobi Swedish Orphan Biovitrum GmbH - € 10,000, Takeda Pharma Vertrieb GmbH & Co. KG - € 5,000. Status: 05/2026

Unser Ziel ist ambitioniert: die Welt ohne Krebs. Unsere Forscher:innen suchen jeden Tag nach medizinischen Lösungen, die das möglich machen können.

Dabei sind die individuellen Bedürfnisse von Menschen mit Krebs unsere größte Motivation: Ihr Leben wollen wir entscheidend verbessern.

So verbinden wir das Beste aus Health&Care:
Medizinische Innovation mit dem Menschen im Mittelpunkt.

jnj.com/innovativemedicine/germany

Johnson&Johnson
The Health&Care Company

www.lymphoma-symposium.de

All information and data correspond to the status at the time of printing. Subject to change.
Despite careful editing, all information is subject to change without guarantee. Status 05/2026.